Cobra Biologics is pleased to announce the appointment of Daniel Smith as Chief Scientific Officer with the responsibility of enhancing Cobra’s DNA, virus, microbial and mammalian proteins research and development platforms.
Dr Smith has spent the last four years with the bioProcessUK team at the HealthTech & Medicines Knowledge Transfer Network (KTN), driving the innovation agenda for biologics bioprocessing in the UK as a Knowledge Transfer Manager. He successfully delivered a number of projects enhancing industrial and academic collaboration as well as innovation in bioprocessing as a Senior Technologist. The experience he has gained at the KTN has enabled him to build an extensive academic and industrial network, including key R&D innovators and opinion leaders.
Prior to work at the KTN, Dr Smith gained his industrial experience at Cobra in a variety of roles progressing from Senior Scientist to Commercial Scientific Development Manager, responsible for developing the strategy for customer’s projects, alongside maintaining scientific oversight of Cobra’s R&D projects.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze